Big Take Podcast
Cheaper, Generic Weight-Loss Drugs Are Coming
On today’s Big Take podcast: Novo Nordisk’s patents on Ozempic are starting to expire. What does that mean for the global weight-loss drug market?
Never miss an episode. Follow The Big Take daily podcast today.
Shares of Novo Nordisk were down Thursday morning after Hims & Hers introduced a compounded version of its Wegovy pill. The dip came two days after Novo predicted its sales could drop as much as 13% this year as the company factors in competition from generic drugs that could crop up as its patents expire around the world.